QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. 期刊论文 CANCER IMMUNOLOGY RESEARCH, 2020, 卷号: 8, 期号: 3, 页码: 70-70 作者:  Dai, Yang;  Ji, Yichun;  Shen, Yanyan;  Su, Yi;  Liu, Bo 收藏  |  浏览/下载：25/0  |  提交时间：2020/07/01 Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models 期刊论文 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 卷号: 38, 期号: 1, 页码: 16 作者:  Peng, Xia;  Hou, Pengcong;  Chen, Yi;  Dai, Yang;  Ji, Yinchun 收藏  |  浏览/下载：6/0  |  提交时间：2020/07/01 Kinase inhibitor  FGFR  CSF-1R  Tumor microenvironment   Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1 期刊论文 Journal of Experimental & Clinical Cancer Research, 2019, 卷号: 38, 期号: 1 作者:  Xia Peng;  Pengcong Hou;  Yi Chen;  Yang Dai;  Yinchun Ji 收藏  |  浏览/下载：1/0  |  提交时间：2021/12/01 Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 148, 页码: 140-153 作者:  Zha, Chuantao;  Deng, Wenjia;  Fu, Yan;  Tang, Shuai;  Lan, Xiaojing 收藏  |  浏览/下载：68/0  |  提交时间：2019/01/08 Structure-based drug design  Selective CDK4/6 inhibitors  Structure-activity relationship study  In vivo antitumor activity   Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors 期刊论文 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 卷号: 27, 期号: 23, 页码: 5332-5336 作者:  Fu, Yan;  Tang, Shuai;  Su, Yi;  Lan, Xiaojing;  Ye, Yan 收藏  |  浏览/下载：26/0  |  提交时间：2019/01/08 Cyclin-dependent kinase  CDK inhibitor  Structure-activity relationship  In vitro and in vivo profiling